Short numbers updated;
07/15/2014 23,241,483 up 4.95% Av vol 3,000,162
06/30/2014 22,145,438 down(13.11%) Av vol 5,319,798
although av vol has decreased by 2.3mil per day short interest has increased by 1.1 mil shares.
My guess is that with last weeks take down short interest has increased since
....what possible catalysts prior to Nov.? The hedge fund shorts are all over this "quiet time" period lapse. Nov is not soon enough.
B) FDA release on hold?
C) MAYO expanding it's study on IMET?
Hydroxyurea can cause a severe decrease in the number of blood cells in your bone marrow. This may cause certain symptoms like neutropenia and may increase the risk that you will develop a serious infection or bleeding. Hydroxyurea even with a 30% response rate it's side effects still beg for other safer far less dangerous alternatives. With Jakafi sharing similar side effects and only a 13% improvement over hydroxyurea the case for IMET has just received another boost from this failed study.
How does INCY claim it's drug is approve-able in PV based on a failed statistical significant trial? Why don't they need FDA approval for PV? The drug has many severe side effects. Where are the ambulance chasers?
...sounds idyllic but I'm not the jealous type. I try to stay clear of the salt water these days with all the Great White sightings come backs. GERNville still has plenty of sharks 8=3(
Marcia, Marcia, Marcia the INCY results just underscore that Jakafi does not work. The market makers are well aware of the potential in IMET hence the manipulated trade activity. This news should have been a huge boost in SP to GERN today yet SP was taken down AGAIN!
Jakafi, the $1billion placebo.
Much of what we see in manipulated trading and FDA actions or lack of can easily be pointed to the INCY lobby, hell bent on protecting their threatened market niche. The drug obviously has very limited use and it's efficacy is questionable yet it has been grandfathered in under no other treatment available fast tracked designation, a status that has not been questioned until Jakafi met IMET. Hands down IMET has proven efficacy and needs to be developed for the greater good of all MF, PV and ET patients.
MM certainly gets it. Look at ASTYV today. 30% drop on only 13,659 vol. GERN's two week trading pattern hasn't faired much better...on what bad news? GAP filled. IBB index has recovered. Yet SP languishes, This is being totally manipulated downwards. Without an update on clinical trials from the company or a clinical lift from the FDA, SP will continue to take such abuse.
What's your prediction Blazer on how low these wall street mouth foaming hedge funds take down the SP before they decide to cover? We're already down to pre-partial lift MAYO news release levels.
....didn't Dr. Tefferi already show the FDA that patients taking imetelstat for MF didn't suffer from any permanent liver damage and those LFT low levels that were detectable were also reversible?
"All of Geron's chips are placed on one drug: imetelstat. Unfortunately for Geron, the pathway to success for the drug hit a roadblock in March. The U.S. Food and Drug Administration placed a full clinical hold on studies of imetelstat targeting essential thrombocythemia and multiple myeloma due to concerns about potential liver problems for patients taking the drug. A few days later, the FDA also placed a partial clinical hold on another study of imetelstat focusing on treatment of myelofibrosis that is being led by Mayo Clinic's Dr. Ayalew Tefferi.
Last month, Geron received a bit of good news as the partial clinical hold on Dr. Tefferi's study was lifted. The clinical trials sponsored by Geron itself, however, are still on hold until the biotech can show the FDA that patients taking imetelstat won't suffer from permanent liver damage.
Assuming that Geron can make a convincing argument for imetelstat, the future could be brighter than the past couple of decades. Dr. Tefferi's research found that some myelofibrosis patients taking the drug went into complete remission. By contrast, the only drug currently approved for myelofibrosis, Incyte's (NASDAQ: INCY ) Jakafi, doesn't boast that kind of efficacy.
Jakafi generated over $235 million in revenue for Incyte last year and is expected to make at least $315 million in 2014. If Geron ultimately navigates the regulatory waters successfully, imetelstat could become an even bigger winner than Jakafi. Any chances of positive earnings, though, are still years away: Geron's drug is still only in phase 2 trials."
IBB up 1.5%, GERN down another 4.78%
$2.76 GAP filled
Asterias shares distributed as per July 22 "Ex-Dividend Date"
And still we decline?
"Problem"? The firm making GERN's market has kept SP down for years. What's wrong with pure & applied market forces fur once?
As to finger pointing, given the market seems to be in a recovering mode this morning (all my biotechs are up cept fur GERN :( Yellen's loud comments on Tuesday may have been the excuse used to tear down GERN's SP by 20%, it seems more likely that the Jakafi lobby is behind all this SP manipulation. They could easily be working with some market funds and are obviously paying shills in the MPN's forum to edit out any relevant info on IMET. Who knows who they may have paid off within the FDA. The MAYO can only go so far with their partial clinical hold being lifted.